Positive results from pivotal Phase III Clinical Trials
29 January 2020
Both trials met their primary endpoint, showing pre-defined equivalence of hyperpolarized 129Xenon Gas MRI to an approved comparator, 133 Xenon Scintigraphy
Company plans for NDA submission to FDA in Q3 2020
Polarean’s technology could offer clinicians a powerful tool to visualise lung function, overcoming limitations of existing methods of diagnosis and monitoring treatment
Polarean Imaging plc (AIM: POLX), a clinical stage medical imaging technology company developing a proprietary magnetic resonance imaging (MRI) drug-device combination, announces positive top-line results from two pivotal Phase III clinical trials (the “Clinical Trials”) of the Company’s drug-device combination, which uses hyperpolarized 129Xenon gas MRI to visualise and quantify regional lung function.
The drug, 129Xenon, when polarised in Polarean’s proprietary system, permits functional, regional and quantitative imaging of the lungs using MRI, without the use of ionizing radiation. 129Xenon is administered as an inhaled gas that is given to patients in a 10-second breath-hold procedure. For patients who participated in the Clinical Trials, the ventilation in zones of interest was quantified and compared to images, similarly quantified, but derived from a different imaging modality.
Phase III Clinical Trials Data Demonstrate Effective Measurement of Regional Lung Ventilation
The two Clinical Trials were multi-center, randomised, open-label studies that compared MRI with 129Xenon gas, polarised in Polarean’s system, to 133Xenon scintigraphy. These tests were used to measure regional pulmonary function in patients being evaluated for possible lung resection surgery and possible lung transplant surgery.
Both Clinical Trials met their primary endpoints, within the prospectively defined equivalence margin (+/-14.7%) when compared to the FDA-approved reference standard, 133Xenon scintigraphy imaging.
Lung Resection Trial
The surgical resection trial of 32 patients, required investigators to specify lung zones that would likely be resected if the patient received resection surgery. This trial compared each imaging modality’s prediction of the proportion of lung function that would remain if the zone(s) were removed, this was expressed as a percentage remaining function. The intra-patient mean difference between 129Xenon MRI-predicted remaining function and 133Xenon scintigraphy-predicted remaining function was 1.4% with a 95% confidence interval of (‑0.75%, 3.60%).
Lung Transplant Trial
In the lung transplant trial of 48 patients, the intra-patient mean difference between the imaging modalities measurement of the contribution of right lung to total lung function (percentage function) was -1.59% with a 95% confidence interval of (-3.69%, 0.50%).
Hyperpolarized 129Xenon gas inhalation and the 10 second breath procedure were well tolerated. Data from these Clinical Trials are being submitted for presentation at an upcoming scientific conference.
In addition, data from the Clinical Trials will form the basis of a Pre-New Drug Application (“NDA”) Meeting with the U.S. Food and Drug Administration (“FDA”). Following the Pre-NDA Meeting and incorporation of the conclusions of the Clinical Trials into the NDA submission, Polarean plans to submit an NDA for the drug-device combination to the FDA, which is now estimated for Q3 2020.
More information on these studies can be found on www.clinicaltrials.gov under the identifiers NCT03417687 (lung resection) and NCT03418090 (lung transplant).
Richard Hullihen, Chief Executive Officer of Polarean said: “The positive results of these Clinical Trials validate our belief that Polarean’s technology allows clinicians to visualise aspects of the lung function, which have never before been visible by MRI, both safely and quantitatively. More than 30 million Americans suffer from a chronic lung disease and the financial burden of lung disease now exceeds US$150 billion annually. Given the limitations of existing methods to diagnose and monitor lung disease, we see a significant unmet need for non-invasive, quantitative and cost-effective image-based diagnosis technology without exposing patients to ionizing radiation. We believe that our technology has the potential to overcome these limitations and we look forward to using data from the Clinical Trials to support our New Drug Application.”
Y. Michael Shim, MD, Director of Pulmonary Rehabilitation and Director of the Pulmonary Function Testing Lab at the University of Virginia, and an investigator on the trials said: “The use of conventional, anatomical MRI has, historically, not played a role in addressing the substantial unmet need in working up difficult-to-diagnose pulmonary diseases. The innovative approach we have taken with the use of hyperpolarized 129Xenon gas opens up a whole new window into how physicians diagnose, stage and monitor responses to treatment in a broad range of lung diseases with this high resolution, non-ionizing MRI method. Based on what has been demonstrated in these Clinical Trials, we are excited about the prospect of having the Company’s technology available as an additional tool to potentially make a clinically significant impact in the future.”
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
|Polarean Imaging plc||www.polarean.com / www.polarean-ir.com|
|Richard Hullihen, Chief Executive Officer||Via Walbrook PR|
|Richard Morgan, Chairman|
|SP Angel Corporate Finance LLP||Tel: +44 (0)20 3470 0470|
|David Hignell / Soltan Tagiev (Corporate Finance)|
|Vadim Alexandre / Rob Rees (Corporate Broking)|
|Walbrook PR||Tel: +44 (0)20 7933 8780 or
|Paul McManus / Anna Dunphy||Mob: +44 (0)7980 541 893/
+44 (0)7879 741 001
About Polarean’s Technology
Polarean's technology produces hyperpolarized inert Xenon gas, used in conjunction with standard MRI to create high-resolution three-dimensional functional maps of the human lung. This technique provides a unique and sensitive way to monitor changes in lung structure and function; it is currently used in basic and clinical research to study lung physiology and to monitor the efficacy of new drugs.
The central equipment required for hyperpolarized gas MRI is a polarizer. Using circularly polarized laser light, the polarizer transforms the inert, stable noble gas isotope 129Xenon into its hyperpolarized state. This process leaves the gas chemically unchanged, while only the nucleus is magnetically aligned. The resulting MRI signal is enhanced by a factor of 100,000, making direct imaging of gas atoms possible.
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (129Xe) as an imaging agent to visualize ventilation.129Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimize the imaging of 129Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.